BMN 270

Baird has initiated coverage on Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) with an Outperform rating, citing diversified pipeline with multiple near-term catalysts. It also upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to Outperform with a $110 price target. Ultragenyx Ultragenyx's...